Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

3 critical monkeypox vaccine questions 

By Brian Buntz | August 2, 2022

Scanning electron micrograph of monkeypox virus which could be treated with monkeypox vaccines

Scanning electron micrograph of monkeypox virus (orange) on the surface of infected VERO E6 cells (green).
[Image courtesy of NIAID]

In the U.S., federal authorities have allowed two vaccines to be used to reduce the risk of monkeypox virus infection. The preferred option is the Jynneos vaccine from Bavarian Nordic (OMX:BAVA), followed by Emergent BioSolutions’ (NYSE:EBS) ACAM2000. 

While vaccination efforts are ramping up, California, New York and Illinois have declared states of emergency as the monkeypox virus spreads. 

As the monkeypox outbreak continues to gain momentum, here are three questions to keep in mind. 

1. How effective are monkeypox vaccines?

CDC notes that the effectiveness of the vaccines is unknown in the current outbreak. 

While some media outlets have reported that the smallpox vaccines are 85% effective in protecting against monkeypox, that figure is based on a small study in Africa from 1988. 

That study followed the household contacts of 209 monkeypox-infected individuals in Zaire.  

Of those, 70% had scars from prior smallpox vaccination. Those vaccinated individuals were 85% less likely to be infected with monkeypox than the remaining 30%.  

The data from the study are “pretty weak,” concluded the University of Florida biostatistician Ira Longini in an interview with MedPage Today. 

Still, Jynneos and ACAM2000 rely on newer, potentially more effective vaccine technology than was available in the 1980s. 

A 2008 study published in PNAS found that a smallpox vaccine offered protection for over two years in a monkeypox virus challenge model involving non-human primates. 

2. Will other monkeypox vaccines enter the fray? 

Monkeypox vaccine doses are in short supply. Bavarian Nordic is planning to close a European production facility until late 2022.

In late July, FDA authorized 786,000 doses to be distributed in the near future following an FDA expedited inspection of Bavarian Nordic’s fill-and-finish capabilities. The U.S. has been working to procure 5.5 million monkeypox vaccine doses for 2023.

A handful of other companies could potentially introduce monkeypox vaccines. Moderna said it engaged in preclinical testing of potential monkeypox vaccines. 

On a related note, Siga Technologies has noted that it has received approximately $13 million worth of orders for its oral smallpox antiviral, Tpoxx (tecovirimat). FDA approved the drug in 2018 based on data from animal studies. Although not authorized specifically for monkeypox, Tpoxx is available as a treatment for the virus through an investigational drug protocol. 

Emergent BioSolutions also acquired the oral antiviral Chimerix’s Tembexa, which won FDA approval in 2021.  

3. Will developing nations continue struggling with monkeypox vaccine access? 

In the COVID-19 pandemic, wealthy nations purchased the bulk of available COVID-19 vaccine doses, leaving those in low and middle-income countries with limited access to vaccines. 

A similar phenomenon appears to be playing out with the monkeypox outbreak. Wealthy countries have yet to announce plans to offer vaccine doses to the developing world. 

The situation could exacerbate health outcomes in regions such as Africa. For example, the Congo Basin strain of monkeypox circulating in the Democratic Republic of the Congo and the Central African Republic is approximately 10 times more lethal than strains circulating elsewhere, according to an article in Science.


Filed Under: Infectious Disease
Tagged With: Bavarian Nordic, CDC, FDA, Jynneos, monkeypox, monkeypox vaccine
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE